Shoving Regenxbio aside, Ultragenyx’s Emil Kakkis closes Dimension buyout deal with 400% premium
Ultragenyx $RARE has won its 11th-hour bid for the troubled gene therapy biotech Dimension Therapeutics $DMTX, which is leaving Regenxbio $RGNX at the altar …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
